Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

被引：23
|
作者：
Girgis, Suzette [1 ,3 ]
Lin, Shun Xin Wang [1 ]
Pillarisetti, Kodandaram [1 ]
Verona, Raluca [1 ]
Vieyra, Diego [1 ]
Casneuf, Tineke [2 ]
Fink, Damien [1 ]
Miao, Xin [1 ]
Chen, Yang [1 ]
Stephenson, Tara [1 ]
Banerjee, Arnob [1 ]
Hilder, Brandi W. [1 ]
Russell, Jeffery [1 ]
Infante, Jeffrey [1 ]
Elsayed, Yusri [1 ]
Smit, Jennifer [1 ]
Goldberg, Jenna D. [1 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Res & Dev LLC, Beerse, Belgium
[3] Janssen Res & Dev, 920 Route 202, Raritan, NJ 08869 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 04期
关键词：
CELL MATURATION ANTIGEN; BONE-MARROW; SURVIVAL;
D O I：
10.1182/bloodadvances.2022007625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：644 / 648
页数：5
相关论文
共 50 条
  • [21] Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
    Davis, James A.
    Snyder, Jordan
    Rice, Mikhaila
    Moore, Donald C.
    Cahoon, Christopher
    Julian, Kelley
    Wagner, Charlotte B.
    Granger, Katelynn
    Green, Kimberly M.
    Atrash, Shebli
    Hill, Hailey
    Mcelwee, Jessica
    Elsey, Grace
    Khouri, Jack
    Rudoni, Joslyn
    Mahmoudjafari, Zahra
    Nachar, Victoria
    BLOOD, 2024, 144 : 2382 - 2383
  • [22] First Results From the RedirecTT-1 Study With Teclistamab (Tec) plus Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Cohen, Yael
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S478 - S479
  • [23] Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
    Grajales-cruz, Ariel
    Graeter, Allison
    Hansen, Doris
    Puglianini, Omar Castaneda
    Vazquez-Martinez, Mariola
    Blue, Brandon
    Liu, Hien
    Ochoa-Bayona, Jose
    Freeman, Ciara
    Locke, Frederick
    Nishihori, Taiga
    Shain, Kenneth
    Baz, Rachid
    Alsina, Melissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S56 - S56
  • [24] Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience
    Feixas, Pablo Tenorio
    Cox, Catrin
    Peer, Xavier
    Cuthill, Kirsty
    Benjamin, Reuben
    Gunawan, Arief
    Cuadrado, Maria
    de Farias, Madson Correia
    Jones, John
    Shin, Jin-Sup
    Batool, Asma
    Bowcock, Stella
    Omer, Musab
    Tawde, Prachi
    Bailey, Katharine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S92
  • [25] Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma
    Taft, David
    Henderson, Clark
    O'Day, Christine
    Yu, Changpu
    Li, Hong
    Ho, Phoenix
    Van Epps, Heather
    BLOOD, 2021, 138
  • [26] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Cohen, Yael C.
    Morillo, Daniel
    Gatt, Moshe E.
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle R.
    Beelen, Melissa Jo
    Vanak, Jill
    Banerjee, Arnob
    Magen, Hila
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Magen, Hila
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S50
  • [28] Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Martin, Thomas
    Wolf, Jeffrey
    Chung, Alfred
    Arora, Shagun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S536 - S537
  • [29] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
  • [30] Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
    Catamero, Donna
    Ray, Chloe
    Purcell, Kiah
    Leahey, Sheryl
    Esler, Elaine
    Rogers, Stephanie
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    Tolbert, Jaszianne
    Renaud, Thomas
    Patel, Saurabh
    Hannemann, Linda
    Shenoy, Samantha
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (05)
12345